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Abstract A major part of the proin£ammatory activity of tu-
mor necrosis factor (TNF) is brought about by cytosolic phos-
pholipase A2 (cPLA2) that generates arachidonic acid, the pre-
cursor for the production of leukotrienes and prostaglandins.
The activation of cPLA2 and induction of proin£ammatory lipid
mediators is in striking contrast to the teleologic meaning of
apoptosis, which is to avoid an in£ammatory reaction. In this
review we highlight the evidence for a caspase-mediated cleav-
age and inactivation of cPLA2, which seems to be an important
mechanism by which TNF downregulates cPLA2 activity in cells
undergoing apoptosis.
& 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Cytosolic phospholipase A2 ;
Tumor necrosis factor; Death domain; Caspase
1. Tumor necrosis factor (TNF) and TNF receptors (TNFRs)
TNF represents the prototype of a gene superfamily of li-
gands that control host defense, in£ammation, apoptosis,
autoimmunity, and organogenesis [1]. Correspondingly, the
receptors for these ligands also constitute a TNFR-related
gene superfamily. Most members of the TNF/TNFR family
are expressed in the immune system, where they coordinate
the protective functions of pathogen-reactive cells. The discov-
ery that cachectin, a protein known to cause fever and wast-
ing, was identical to TNF early on suggested that TNF and its
related ligands/receptors are not only protective but can play
an important role in human disease. Indeed, anti-TNF anti-
bodies or pharmaceutical inhibitors of TNF have been devel-
oped which are now clinically employed to ameliorate in£am-
matory conditions like rheumatoid arthritis and in£ammatory
bowel disease that previously proved resistant to conventional
antiphlogistic modalities [2].
2. Role of TNF in apoptosis and in£ammation
Much is known about how TNF induces programmed cell
death (apoptosis) [3]. On the molecular level, apoptosis in-
volves evolutionarily conserved pathways of caspase activa-
tion resulting in shrinkage, compaction, and breakdown of
the cell into easily phagocytosed membrane-surrounded bits.
Purely apoptotic pathways may be involved in tissue remod-
eling during development or wound repair. It should be em-
phasized that apoptosis is unable to explain all the death
capabilities of TNFRs. TNF also induces cellular necrosis
involving swelling or bursting of the cell with organelle degen-
eration and loss of plasma membrane integrity [4]. In general
apoptosis is not found with in£ammation. In contrast, ne-
crotic cell death may be extremely important for activating
the immune system when TNF-induced necrosis is part of
an anti-pathogen response. Thus, the proapoptotic and proin-
£ammatory e¡ects of TNF seem to be mutually exclusive, or
at least opposing activities. In the present review, we will
propel the idea that one physiological role of the TNF-respon-
sive caspases is to curb the proin£ammatory response which
might even operate in the absence of apoptotic cell death.
3. TNFR signaling
TNFR-like receptors have unique structural features that
couple them directly to signaling pathways controlling cell
proliferation, di¡erentiation, activation, and cell death. The
hallmark of the TNFR superfamily are pseudorepeats in the
extracellular parts typically de¢ned by three intrachain disul-
¢des generated by six highly conserved cysteines [5]. Recent
evidence has shown that TNFR self-assemble in the absence
of ligand and signaling involves rearrangement of the preas-
sembled chains [6].
TNFR signaling occurs through two principal classes of
cytoplasmic adapter proteins: TRAFs (TNFR-associated fac-
tors) and ‘death domain’ (DD) molecules [7]. The signaling
adapter is selected depending on whether the cytoplasmic do-
main of the receptor contains either a TRAF binding motif or
a DD. The TRAF binding motif is a stretch of amino acids in
the receptor tail that is clutched by a pocket in the globular
head group of the adapter through charged residues [1].
TRAF1 and TRAF2 were the ¢rst receptor-associated factors
identi¢ed and shown to interact with the p75 TNFR (TNFR2)
[8]. In contrast, the DD is a 60 amino acid globular bundle of
six conserved K-helices found in the receptor tail and the
adapter that promotes homotypic association [9]. The p55
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TNFR type 1 (TNFR1) through its DD binds the adapter
protein TRADD (TNFR-associated DD protein) that itself
harbors a DD. TRADD ultimately causes caspase activation
and cell death. Since most cellular TNF responses including
the activation of cytosolic phospholipase A2 (cPLA2) are
mediated by TNFR1, this review will focus on the signaling
of this receptor.
TNFR1 signals rarely result in apoptosis but can trigger
several pathways that lead to cell activation, di¡erentiation,
or apoptosis (Fig. 1). This is brought about by di¡erent
adapter proteins that associate with TRADD [7]. At least
three proteins can be recruited to TRADD: TRAF2, RIP,
and FADD. A large body of evidence indicates that TRAF2
mediates the activation of the c-Jun N-terminal kinase (JNK),
RIP is essentially involved in the NF-UB activation pathway,
and FADD signals apoptosis through activation of caspase-8.
The adapter proteins signaling the phosphorylation and acti-
vation of extracellular signal-regulated kinases 1/2 (ERK1/2)
have not yet been unambiguously identi¢ed. These adapter
proteins provide a modularity that allows a regulatory £exi-
bility of TNFR1 signaling events which seems to be required
to warrant a speci¢c response among such con£icting signals
like cell activation and apoptosis.
4. TNFR1-mediated activation of cPLA2
How TNF signals the activation of cPLA2 is not fully
understood. cPLA2 is an 85 kDa protein (Fig. 2) that prefer-
entially liberates arachidonic acid (AA) from the sn-2 position
of phospholipid generating lysophospholipid and free AA
[19]. AA can be converted to potent in£ammatory lipid medi-
ators, the eicosanoids. This conversion occurs enzymatically
through the lipoxygenase or cyclooxygenase pathways for the
production of leukotrienes, lipoxins, thromboxanes, or pros-
taglandins. The important role of AA in the regulation of an
in£ammatory response requires that its levels be tightly con-
trolled. cPLA2 plays a major role in maintaining AA levels,
and its enzymatic activity is subject to complex regulatory
mechanisms [11]. At least two receptor-mediated events have
been identi¢ed leading to PLA2 activation: the binding of
calcium promotes translocation of cPLA2 to membranes
[12], while phosphorylation at Ser505 of cPLA2 directly in-
creases its activity [13]. Activation of cPLA2 occurs in many
cell types in response to various stimuli [10]. In particular,
cPLA2 can be activated by the death receptors TNFR1 and
CD95, which also mediate apoptosis [14]. Thus, two con£ict-
ing signals, apoptosis and production of in£ammatory medi-
Fig. 1. Signaling pathways emanating from the TNFR1 DD.
Fig. 2. Schematic representation of the primary structure of cPLA2.
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ators, can emanate from these receptors which, however, are
not supposed to coincide.
Based on published evidence from many investigators, a
model was proposed where the PLA2 activation pathway em-
anating from the TNFR1 involves a ceramide-activated pro-
tein kinase (CAPK) that phosphorylates and activates Raf-1
kinase, which eventually results in phosphorylation and acti-
vation of ERK1/2 [14]. ERK1/2 in turn have been shown to
phosphorylate and thereby activate cPLA2 [13]. It has been
suggested that CAPK is identical with KSR, the kinase re-
pressor of Ras [15]. However, the topology and sequence of
events leading to the generation of ceramide stimulating the
putative CAPK are rather elusive. It was previously proposed
that the TNF-responsive, plasma membrane-associated
N-sphingomyelinase (N-SMase) provides the CAPK-targeted
ceramide [15]. This idea was dismissed, because TNFR1-in-
duced N-SMase activation involves a ‘private’ signaling path-
way that is distinct from that required for PLA2 activation.
TNFR1 signals N-SMase activation through a speci¢c do-
main termed NSD for N-SMase activating domain [16]. The
adapter protein FAN speci¢cally binds to the NSD and me-
diates activation of N-SMase [17]. By employing two di¡erent
types of transgenic mice either de¢cient for FAN or solely
lacking an intact TNFR1 DD, we have recently provided
genetic evidence that the activation of both ERK and cPLA2
does not require FAN and/or N-SMase but rather is depen-
dent on the presence of a functional DD [18].
The idea that TNF-induced activation of ERK and/or
cPLA2 is coupled to the DD of TNFR1 is in agreement
with recent observations from other investigators: (i) Boone
et al. showed by analyzing TNFR1 mutants stably expressed
in L929 cells that TNF induces ERK activation through the
DD of TNFR1 [19]. (ii) TNF-induced cPLA2 phosphorylation
in human neutrophils was found to be downstream of the
TNFR1 DD and to be mediated by p38 MAPK [20]. The
activity of p38 MAPK appeared to be regulated by TRAF2
that indirectly interacts with the DD. (iii) RIP2, the receptor-
interacting protein 2, has also been shown to mediate TNF-
dependent ERK1/2 activation [21]. Since RIP2 belongs to the
family of TNFR1 DD binding proteins, this observation also
links ERK1/2 activation to the TNFR1 DD. (iv) MADD, a
TNFR1-interacting DD protein has been reported as a regu-
lator of TNF-induced ERK1/2 and cPLA2 activation [22].
(v) Finally, Tschopp and his coworkers reported that the
FADD binding protein FLIP (FLICE-like inhibitory protein)
interacts with the protein kinase Raf-1 resulting in the activa-
tion of ERK [23]. While these reports couple various adapter
proteins to ERK1/2 and/or cPLA2 activation, these proteins
have in common that they bind to the TNFR1 DD. Thus the
picture emerges that TNF-induced cPLA2 phosphorylation
and activation is triggered through the DD involving the
adapter proteins TRADD, FADD and possibly FLIP or
RIP2, which results in the activation of protein kinases Raf-1
and ERK1/2 (Figs. 1 and 3).
5. Caspase-mediated inhibition of cPLA2
cPLA2 belongs to the family of numerous substrates that
are cleaved by caspases [24^27]. In vitro studies using in vitro
translated cPLA2 and recombinant caspases have shown that
cPLA2 can be hydrolyzed by caspase-3, -7, and -8. The ob-
served cleavage products of 70 and 32 kDa corresponded to
both protein fragments expected after cleavage at the cognate
caspase-3 motif DELD present at amino acids 519^522 of the
primary cPLA2 structure (Fig. 2). Although the molecular
mass of cPLA2 deduced from its amino acid sequence is 85
kDa, the native enzyme migrates on sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) in the range
of 100^110 kDa. The calculated size of the cleavage products
would be 59 and 26 kDa, respectively. Since both fragments
demonstrate a higher molecular mass on SDS^PAGE, the
amino acid sequences responsible for the abnormal migration
behavior of cPLA2 are apparently distributed in both cleavage
products. When caspases were overexpressed in intact cells, at
least ¢ve caspases (caspase-1, -3, -4, -7, and -8) produced
discrete cleavage patterns of cPLA2. For example, caspase-1
generated mainly a p58 fragment, while caspase-3 and -4 gen-
erated mainly p70. Site-speci¢c mutation analysis showed that
caspase-3 and -8 cleave cPLA2 at the aspartic acid residue
522, while caspase-1 can cleave human cPLA2 at the YQSD
Fig. 3. TNFR1-mediated activation and inactivation of cPLA2.
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motif (amino acid residues 456^459) [18,25,26]. It should be
noted that overexpression of a single caspase together with
cPLA2 likely leads to direct cleavage, but might additionally
stimulate the apoptotic program of the cell and, thus, the
activation of other caspases that eventually also cleave cPLA2.
Thus, the results from cleavage assays in intact cells probably
re£ect a mixture of fragments generated by direct and indirect
processing. It is important to emphasize that the presence of
multiple cleavage sites for various caspases assures cleavage of
the proin£ammatory enzyme cPLA2 in any context leading to
apoptosis.
In an earlier report, Wissing et al. showed cleavage of hu-
man cPLA2 to a 70 kDa fragment by a caspase-3-like activity
[24]. Based on their observation that the tetrapeptide inhibitor
of caspase-3 Ac-DEVD-CHO inhibited both TNF-induced
apoptosis and release of AA, these investigators suggested
that caspase-mediated cleavage of cPLA2 results in the acti-
vation of this enzyme. It is, however, highly unlikely that
either one of the cPLA2 fragments resulting from the cas-
pase-mediated cleavage at aspartic acid residue 522 (the
N-terminal 70 kDa or the C-terminal 32 kDa fragment) can
be catalytically active: Previous structure function analysis of
cPLA2 revealed residues 200, 228, 331, and 549, located
N-terminally as well as C-terminally of the cleavage site at
residue 522, to be essential for the catalytic function of cPLA2
[28]. Indeed, cPLA2 activity has not been assayed directly in
the Wissing et al. study and the release of AA from apoptotic
cells previously labeled with 3H-AA might have been brought
about non-speci¢cally [29] or by enzymes other than cPLA2
[30]. In fact, it has been suggested that the PLA2 isozyme
responsible for increased arachidonic acid release during ap-
optosis may be Ca2þ-independent PLA2 [30].
We and others have recently demonstrated that caspase-
mediated cleavage of cPLA2 results, indeed, in the inactiva-
tion of its enzymatic activity [25,27]. As predicted from the
positions of catalytically essential residues, a recombinant 70
kDa cPLA2 fragment corresponding to the 70 kDa cleavage
product had no enzymatic activity, when overexpressed in
HEK 293 cells. This indicates that cleavage of cPLA2 at the
DELD motif results in inactivation of the enzyme. In addi-
tion, mutation of the cognate caspase-3 DELD motif abol-
ished cPLA2 processing in intact cells and lead to increased
cPLA2 activity in TNF-stimulated HEK 293 cells. Increased
cPLA2 activity after inhibition of caspase-mediated cleavage
strongly suggests that caspases downregulate if not terminate
cPLA2 activation by hydrolysis into two catalytically dead
fragments.
Interestingly, overexpression of the 70 kDa cleavage prod-
uct of cPLA2 not only showed no detectable enzymatic activ-
ity, but exhibited a dominant negative e¡ect on the TNF-
induced activation of endogenous cPLA2 [25,30]. A possible
explanation might be that the truncated cPLA2 competes for
binding of cofactors necessary for the activation process. Such
cofactors are calcium ions or proteins phosphorylating
cPLA2. Since both the calcium binding domain (CaLB) and
the phosphorylation site are still contained in the functionally
inert 70 kDa PLA2 fragment, this overexpressed truncated
cPLA2 would e⁄ciently compete for calcium ions or protein
kinases. In fact, the catalytically inactive N-terminal fragment
was found to be constitutively located at cellular membranes
thus potentially inhibiting the stimulus-dependent transloca-
tion of native cPLA2 [30]. Therefore, a quantitative cleavage
of cPLA2 after stimulation of caspase activity during apopto-
sis leading to high levels of truncated cPLA2 might downre-
gulate the activity of the remaining intact cPLA2. Indeed, ar-
achidonic acid release after stimulation with calcium
ionophore as well as after interleukin-1 treatment is attenu-
ated upon overexpression of the 70 kDa cleavage product of
cPLA2. Moreover, the dominant negative N-terminal frag-
ment of cPLA2 was also shown to inhibit arachidonic acid
release induced by soluble PLA2-IIA, but not by soluble
PLA2-X [30]. Taken together, caspase-mediated cleavage of
cPLA2 during apoptosis leads to a complete inability of a
cell to produce eicosanoids in response to extracellular stimuli.
Many ligands of the TNFR superfamily can induce apopto-
sis but also activate cPLA2. If both of these actions took place
in the same cell, an in£ammatory signal would coincide with
the apoptotic program that is not meant to lead to an in£am-
matory response. Thus, the cleavage of cPLA2 by caspases
might be an important mechanism that ensures physiologic,
programmed cell death to occur in the absence of an in£am-
matory response.
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